GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$40.80 USD
-0.82 (-1.97%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $40.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
GSK 40.80 -0.82(-1.97%)
Will GSK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
Other News for GSK
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Notable Two Hundred Day Moving Average Cross - GSK
GSK May 2025 Options Begin Trading
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
GSK settles two Zantac lawsuits in California